vapendavir

Small moleculeexperimental

Clinical trial activity

9 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2010 (NCT01175226)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1noc2cc(OCCC3CCN(c4ccc(C)nn4)CC3)ccc12
Mol. weight
382.46 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bta798
  • bta798
  • vapendavir
  • vapendavir

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06834295Phase 1/Phase 2 (Phase 2)Mar 12, 2025Altesa Biosciences, Inc.
NCT06149494Phase 2Nov 20, 2023Altesa Biosciences, Inc.
NCT05962645Phase 1May 19, 2023Altesa Biosciences, Inc.
NCT03024177Phase 2Jan 12, 2017Aviragen Therapeutics
NCT02877264Phase 1Jun 1, 2016Aviragen Therapeutics
NCT02367313Phase 2Feb 1, 2015Aviragen Therapeutics
NCT02204501Phase 1May 1, 2014Aviragen Therapeutics, Prism Research
NCT02101866Phase 1Mar 1, 2014Aviragen Therapeutics, Prism Research
NCT01175226Phase 2Aug 1, 2010Aviragen Therapeutics
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Aviragen TherapeuticsFor profit6622010
Altesa Biosciences, Inc.For profit3322023
Prism ResearchFor profit2012014
3 organizations
Page 1 / 1